Minouk J. Schoemaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minouk J. Schoemaker has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Anthony J. Swerdlow
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom
217 shared publications - Michael E. Jones
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK
135 shared publications - Anna Jakubowska
Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
106 shared publications - Jan Lubiński
Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland
99 shared publications - Paul David Peter Pharoah
Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA
85 shared publications - Usha Menon
University College London, London, United Kingdom
83 shared publications
Latest Publications
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Figure 3 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples (27) are shown, as well as alterations in immune genes and CCNE1. Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS < 2 years), tumor CHORD (41) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status (BRCA1-type HRD; BRCA2-type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Genomic landscape of high-grade serous ovarian tumors with co-occurring BRCA and RB1 alterations. A, Pathogenic germline and somatic alterations in HR and DNA repair genes detected by whole-genome sequencing and DNA methylation analysis of 126 primary HGSC samples (27) are shown, as well as alterations in immune genes and CCNE1. Samples are grouped by HR and RB1 status. Bars at the top indicate the number of alterations in each listed gene per patient. Patients are annotated with survival group (LTS, long-term survivor, OS > 10 years; MTS, mid-term survivor, OS 2–10 years; STS, short-term survivor, OS < 2 years), tumor CHORD (41) scores, and the proportion of structural variant (SV) type (DEL, deletion; DUP, duplication; INV, inversion; ITX, intra-chromosomal translocation). B, Kaplan–Meier estimates of progression-free survival (left) and overall survival (right) of patients according to HR status (BRCA1-type HRD; BRCA2-type HRD; or HRP tumors) and RB1 status (altered vs. wild-type).
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S12 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S12. Clinical characteristics of patients with HGSC.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S12 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S12. Clinical characteristics of patients with HGSC.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S17 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S17 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S17 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S17 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S17. Half maximum inhibitory concentrations (IC50) for cisplatin (72 hours), paclitaxel (72 hours), or olaparib (120 hours) in HGSC cell lines with innate RB1 and/or BRCA1 alterations.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Sensitivity to therapeutic agents in BRCA1-altered cell lines with RB1 knockout. A,RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 (BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 (n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control (n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P < 0.05; **, P < 0.01). Representative scans of the fixed cell colonies stained with crystal violet are shown for each condition.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Sensitivity to therapeutic agents in BRCA1-altered cell lines with RB1 knockout. A,RB1 was knocked out using CRISPR/Cas9 in three patient-derived Australian Ovarian Cancer Study (AOCS) HGSC cell lines with either wild-type or altered BRCA1 (BRCA1 var) background. Representative Western Blots show protein levels of RB1 and phosphorylated RB1 (pRB1) compared with GAPDH loading control in single-cell cloned, homozygous RB1 wild-type (WT) and knockout (KO) colonies in comparison with heterogeneous populations with a scramble single guide RNA (sgRNA). Independent blots were used for RB1 and pRB1. B, Cell viability was compared between RB1 WT and KO clones following treatment with cisplatin (72 h), paclitaxel (72 h), or olaparib (120 h). Nonlinear regression drug curves are shown; P values are shown in Supplementary Table S18 (n = 3). Error bars indicate ± SEM; for some values, error bars are shorter than the symbols and thus are not visible. C, Proportion of surviving colonies following 16 days of treatment with cisplatin, paclitaxel, or a combination of both (Cis/Pac; with half of the IC50 determined per drug and cell line respectively) relative to DMF vehicle control (n = 3 replicates). Data are presented as mean ± SEM. Mean values were compared by Student’s t test (ns, not significant; *, P < 0.05; **, P < 0.01). Representative scans of the fixed cell colonies stained with crystal violet are shown for each condition.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S4. HGSC cell lines with innate RB1 and/or BRCA1 alterations.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S4. HGSC cell lines with innate RB1 and/or BRCA1 alterations.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S14 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S14 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S14. Multivariable adjusted association of molecular alterations and overall survival in ENOC among patients with grade information.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S8. Gene alterations across BRCA and RB1 altered subgroups.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Figure S8. Gene alterations across BRCA and RB1 altered subgroups.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S20 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S20. Immune cell type (LM22) absolute abundance in 126 primary HGSC tumors with CIBERSORTx.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S20 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Supplementary Table S20. Immune cell type (LM22) absolute abundance in 126 primary HGSC tumors with CIBERSORTx.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Expression of RB1 and survival associations across ovarian cancer histotypes. A, Representative images of IHC detection of RB1 expression in ovarian carcinoma tissues, showing examples of the three most common expression patterns: retained, lost, and subclonal loss. B, Proportion of patients with loss or retention of RB1 protein expression in tumor samples by ovarian cancer histotypes. χ2P value reported for difference in proportions across all histotypes. CCOC, clear cell ovarian cancer; LGSC, low-grade serous carcinoma; MOC, mucinous ovarian cancer. C, Boxplots show RB1 mRNA expression (NanoString) by RB1 protein expression status; lines indicate median and whiskers show range (Mann–Whitney test P value reported). Kaplan–Meier analysis of OS in patients diagnosed with HGSC (D) and ENOC (E) stratified by tumor RB1 expression. F, Frequency of germline BRCA wild-type (gBRCAwt) and germline BRCA pathogenic variants (gBRCAvar) in patients with HGSC stratified by RB1 protein expression. χ2P value is reported. G, Kaplan–Meier estimates of overall survival in patients with HGSC by combined germline BRCA and tumor RB1 expression status.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Expression of RB1 and survival associations across ovarian cancer histotypes. A, Representative images of IHC detection of RB1 expression in ovarian carcinoma tissues, showing examples of the three most common expression patterns: retained, lost, and subclonal loss. B, Proportion of patients with loss or retention of RB1 protein expression in tumor samples by ovarian cancer histotypes. χ2P value reported for difference in proportions across all histotypes. CCOC, clear cell ovarian cancer; LGSC, low-grade serous carcinoma; MOC, mucinous ovarian cancer. C, Boxplots show RB1 mRNA expression (NanoString) by RB1 protein expression status; lines indicate median and whiskers show range (Mann–Whitney test P value reported). Kaplan–Meier analysis of OS in patients diagnosed with HGSC (D) and ENOC (E) stratified by tumor RB1 expression. F, Frequency of germline BRCA wild-type (gBRCAwt) and germline BRCA pathogenic variants (gBRCAvar) in patients with HGSC stratified by RB1 protein expression. χ2P value is reported. G, Kaplan–Meier estimates of overall survival in patients with HGSC by combined germline BRCA and tumor RB1 expression status.